Irinotecan Sun

Irinotecan, the active ingredient in Irinotecan Sun, is a topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is used in oncology to target colorectal cancer pathways.

Metastatic colorectal cancer: improves overall survival when incorporated into combination chemotherapy regimens.

Irinotecan may cause a range of adverse reactions, varying from common to serious.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: general tiredness experienced during treatment. - Alopecia: temporary hair loss. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis or intestinal perforation: life‑threatening gastrointestinal complications. - Hepatotoxicity: significant liver enzyme elevations. - Severe allergic reactions: including anaphylaxis. - Acute cholinergic syndrome: bradycardia, sweating, and bronchospasm. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

When administering Irinotecan, clinicians should observe several safety measures.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: check hepatic enzymes before and during therapy. Evaluate gastrointestinal status: avoid use in patients with recent bowel surgery or obstruction. Check for hypersensitivity: discontinue if allergic reactions occur. Pregnancy and lactation: use only if potential benefits justify the risks to the fetus or infant. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia and diarrhea. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations, heightening toxicity. - Concurrent abdominal radiotherapy: may exacerbate gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce drug exposure, potentially lowering efficacy. - Anticholinergic agents: may worsen constipation and affect bowel motility.